Literature DB >> 11976832

Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells.

Kazuya Fukuoka1, Hitoshi Arioka, Yasuo Iwamoto, Hisao Fukumoto, Hirokazu Kurokawa, Tomoyuki Ishida, Akira Tomonari, Toshihiro Suzuki, Jitsuo Usuda, Fumihiko Kanzawa, Hiroshi Kimura, Nagahiro Saijo, Kazuto Nishio.   

Abstract

Vinorelbine (Navelbine, KW-2307), a semisynthetic vinca alkaloid, is a potent inhibitor of mitotic microtubule polymerization. The aims of this study were to demonstrate vinorelbine-induced radiosensitization of human small cell lung cancer (SCLC) SBC-3 cells and to elucidate the mechanisms of radiosensitization. A clonogenic assay demonstrated that SBC-3 cells were sensitized to radiation by vinorelbine using different schedules combining exposure to both. The sensitizer enhancement ratios (SERs) at a cell survival level of 10% were 1.42+/-0.21 to 1.33+/-0.06, and 1.22+/-0.07 depending on schedule. Vinorelbine-induced radiosensitization did not depend on the schedule of the combined exposure. Flow cytometric analyses showed that the cells did not accumulate in the radiosensitive G(2)/M phase of the cell cycle after concurrent treatment with vinorelbine and radiation. The results of an alkaline filter elution assay demonstrated that in the presence of vinorelbine at 1 n M radiation-induced DNA strand breaks were not completely repaired at 24 h postradiation. We conclude that human SCLC SBC-3 cells are sensitized to radiation by vinorelbine and that a possible mechanisms of vinorelbine-induced radiosensitization may at least in part be associated with impairment of DNA repair following radiation-induced DNA damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976832     DOI: 10.1007/s00280-002-0430-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer.

Authors:  Masashi Kobayashi; Kaoru Matsui; Tomonori Hirashima; Takashi Nitta; Shinji Sasada; Takuhito Tada; Kazuo Minakuchi; Mitsugi Furukawa; Yoshitaka Ogata; Ichiro Kawase
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

Review 2.  Pharmacotherapy options for locally advanced and advanced cervical cancer.

Authors:  Alfonso Dueñas-González; Lucely Cetina; Jaime Coronel; Déborah Martínez-Baños
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

3.  Radiosensitizers in cervical cancer. Cisplatin and beyond.

Authors:  Myrna Candelaria; Alicia Garcia-Arias; Lucely Cetina; Alfonso Dueñas-Gonzalez
Journal:  Radiat Oncol       Date:  2006-05-08       Impact factor: 3.481

4.  Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.

Authors:  Cindy Simoens; Filip Lardon; Bea Pauwels; Christel M J De Pooter; Hilde A J Lambrechts; Greet G O Pattyn; Fabienne Breillout; Jan B Vermorken
Journal:  BMC Cancer       Date:  2008-02-29       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.